Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone

Introduction At least 30% of people living with HIV (PLWH) infection have non-alcoholic fatty liver disease (NAFLD), which has now become a leading cause of hepatic fibrosis and cirrhosis. Management is based largely on lifestyle modifications, which are difficult to achieve, and therapeutic options...

Full description

Bibliographic Details
Main Authors: Nicky Perry, Yvonne Gilleece, Sumita Verma, Stephen Bremner, Daniel Bradshaw, Iga Abramowicz
Format: Article
Published: BMJ Publishing Group 2020-07-01
Series:BMJ Open
Online Access: